IMGN News and Press, ImmunoGen Inc. From 03/10/22

Data from Pivotal Trial to be Highlighted in Oral Presentation on Saturday, March 19 Investor Event to be Held Sunday, March 20 at 7:30 am MST ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of ...

Better-than-expected SORAYA results for the use of mirvetuximab against ovarian cancer. Deal with Lilly to de-risk the business. Strong cash position that can fund operations until 2024. For further details see: ImmunoGen: Going In The Right Direction For Ovarian Cancer ...

Image source: The Motley Fool. ImmunoGen (NASDAQ: IMGN) Q4 2021 Earnings Call Feb 25, 2022 , 8:00 a.m. ET Operator Continue reading For further details see: ImmunoGen (IMGN) Q4 2021 Earnings Call Transcript

ImmunoGen, Inc. (IMGN) Q4 2021 Earnings Conference Call February 24, 2022 08:00 ET Company Participants Courtney O'Konek - Senior Director, Corporate Communications & Investor Relations Mark Enyedy - President & Chief Executive Officer Anna Berkenblit - Chief Medical Officer Susan Alt...

ImmunoGen press release (NASDAQ:IMGN): Q4 GAAP EPS of -$0.17 beats by $0.01. Revenue of $28M (-67.4% Y/Y) beats by $2.07M. For 2022, ImmunoGen expects: revenues between $75 million and $85 million vs. $64.5M consensus. operating expenses between $285 million and $295 million; and cash and cas...

Positive Top-Line Data from Pivotal SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer; Detailed Results to be Presented in Plenary Session at SGO in March Mirvetuximab BLA On Track for Submission this Quarter IMGN632 Triplet Data Demonstrating Manageable Safe...

ImmunoGen (NASDAQ:IMGN) is scheduled to announce Q4 earnings results on Friday, February 25th, before market open. The consensus EPS Estimate is -$0.18 (-212.5% Y/Y) and the consensus Revenue Estimate is $25.65M (-70.1% Y/Y). Over the last 3 months, EPS estimates have seen 5 upward revisions ...

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Mark Enyedy, President and CEO, will participate in the ovarian cancer panel discussion at the upcoming Cowen 42nd Annual Health Care ...

AES,OTCPK:ARNGF,OTCQX:BASFY,BHVN,CGAU,CIO,CLMT,CM,CM,CNK,CRI,DSX,DTM,EOSE,EVRG,FL,FWONA,GTN,GVA,OTCPK:ICAGY,IEP,IMGN,LAMR,LI,LSXMK,NOG,OTCPK:NTIOF,NWN,OCGN,OCN,PNW,PSO,QRTEA,SLCA,SMLP,SRE,SSP,STRA,STWD,TREE,UNIT,VST For Seeking Alpha's full earnings season calendar, click here. For fur...

ImmunoGen (NASDAQ:IMGN) shares have added ~3% in the pre-market on Tuesday after the company announced a licensing deal with Eli Lilly (NYSE:LLY) to research, develop, and commercialize antibody-drug conjugates based on its camptothecin platform. ADCs covered by the deal will be dir...